Center of excellence for Arrhythmogenic Right Ventricular Cardiomyopathy in Zurich

Since 2011 we have established the interdisciplinary clinical and scientific Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Program at the University Hospital Zurich as a national and international center of excellence for this disease. This program’s clinical and research goals include the optimization of the interdisciplinary team-work for complex cases, state-of-the-art imaging, optimal therapy for progressive disease, ICD-therapy, catheter ablation, genetic testing and genetic counseling. We have started assembling a large clinical registry of ARVC patients and their family members in order to investigate clinical and genetic factors conferring an increased risk for disease manifestation, progression and a worse outcome. Furthermore, we have installed a multicenter ARVC biobank to study the molecular basis of ARVC and to define novel molecular mechanisms implicated in this complex disease.

Our multidisciplinary Zurich ARVC Program is kindly supported by the “Georg und Bertha Schwyzer-Winiker Stiftung”, the “Baugarten Stiftung”, the University of Zurich, and the Swiss National Science Foundation (SNF).